R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

R&D

The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.

R&D

Find out more about optimising sponsor/CRO collaboration in an interview on a case study in FI cell therapy.

R&D

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

R&D

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.